Researchers conducted a prospective trial to learn more about the clinical value of intra-arterial tenecteplase for acute stroke survivors following successful endovascular therapy. The study population consisted of 256 adults with acute large vessel occlusion who were treated at one of 19 Chinese facilities within 4.5-24 hours of symptom onset. Following successful thrombectomy, patients were randomized 1:1 to 1.25 mg/kg of intra-arterial tenecteplase or to usual care. The primary outcome was excellent functional outcome at 3 months, based on a score of 0 or 1 out of 6 on the modified Rankin Scale. Among the intervention group, 40.5% of participants achieved excellent neurological outcome by 90-day follow-up vs. 26.4% of the controls. Spontaneous intracerebral hemorrhage within 48 hours and mortality within 90 days occurred with no greater frequency in the intra-arterial tenecteplase recipients than in patients receiving standard care, the study authors reported.